Interspond

Interspond is a Trial Management Organization (TMO) founded in 2003. The founder of Interspond, Kathy S. Cox, started one of the first TMOs in the industry in 1996. The business model from that early TMO was used to create Interspond. As a TMO the company seeks to identify study opportunities for the sites with which the company works. The company... then work to get sites selected for participation in clinical trials and facilitate the study start-up process for those selected sites. The company works with sites across the United States that are multi-therapeutic in nature. Recently, Interspond signed an agreement to provide exclusive business development services to a network of neurology/rheumatology/ophthalmology sites. As a result, Interspond now has a hybrid model working with sites on an exclusive and non-exclusive (affiliated) basis. Interspond provides exceptional value to Sponsors and CROs by quickly identifying qualified clinical research sites for participation in phase 2 through 4 clinical research studies. The company then work closely with the Sponsor or CRO in executing a Confidentiality Disclosure Agreement (CDA), facilitating the completion and submission of the Feasibility Questionnaire (FQ), assisting in the scheduling of a Pre-Study Site Visit (PSSV), overseeing the completion and submission of the regulatory documents, and negotiating the contract and budget. The company is ultimately responsible for paying the site's the agreed upon budget, processing invoices, and reconciling study payments.Read More